Trial Profile
6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients versus a slower dose tapering and lower starting dose of Avagraf
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms S & L
- 02 Aug 2022 Planned End Date changed from 1 Dec 2019 to 1 Dec 2025.
- 03 Feb 2020 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2020.
- 02 Jul 2019 this trial is completed at Germany, as per EuropeanClinical Trials Database record.